Semra SALİMOĞLU, Sümeyye EKMEKÇİ, Tayfun KAYA, Batuhan EYDURAN

NADİR GÖRÜLEN MEME TÜMÖRLERİNİN RETROSPEKTİF ANALİZİ

Giriş: Meme kanseri, farklı patolojik özellikler ve biyolojik alt gruplar ile çok farklı klinik davranışlar gösterebilir. Üçüncü basamak genel cerrahi kliniğinde opere edilmiş nadir meme tümörlerinin klinik ve demografik özelliklerini sunmayı amaçladık. Gereç ve Yöntem: Ocak 2010-Ocak 2021 tarihleri arasında meme kanseri nedeniyle opere edilen 2427 hastanın definitif patoloji sonuçları retrospektif olarak incelendi. İnvaziv lobüler karsinom ve invaziv duktal karsinom haricinde bir meme tümörü saptanan 108 hasta çalışmaya dahil edildi. Hastaların cerrahi tipleri, patolojik tanıları, tümör derecesi, ciltte ülserasyon varlığı, aksilla durumu, neoadjuvan ve adjuvan tedavi alma durumları, nüks ve metastaz durumları ve sağkalım süreleri incelendi. Bulgular: Çalışmaya dahil edilen hastaların yaşları 30-87 (yıl) aralığında olup medyan yaş 54’tür. Tümörlerin 41’i (%38,0) papiller karsinom, 20’si (%18,5) metaplastik karsinom, 15’i (%13,9) müsinöz karsinom, 9’u (%8,3) apokrin karsinom, 8’i (%7,4) medüller karsinom, 7’si (%6,5) malign filloid tümör, 3‘ü (%2,8) asinik hücreli karsinom, 2’si (%1,9) granüler hücreli karsinom,1’i (%0,9) anjiosarkom, 1’i (%0,9) over karsinomun meme metastazı, 1’i (%0,9) schwannom olarak tanı almıştır. Hastaların 60’ına (%55,6) meme koruyucu, 34’üne (%31,5) mastektomi operasyonu uygulandı. Hastaların 7’sinde memede ülserasyon görülmüş olup, 5 tanesi metaplastik karsinom, biri medüller karsinom diğeri anjiosarkom saptanan hastaydı. Toplamda 108 hastanın 16’sında (%14,8) birden fazla tümör olduğu görüldü. 16 hastanın 11’i (%68,5) papiller karsinom olarak saptanmıştır. Hastaların postoperatif takip süresi 2-248 ay aralığında olup postoperatif takip süresi medyan 64 aydır. Exitus olan hasta sayısı 25’tir (%23,1). Sonuç: Memede nadir görülen tümörlerin davranışsal özellikleri,daha sık görülen tümör tiplerinden farklı olabilir. Bu davranış farklılıkları, hastalarda beklenen sağkalım oranını ve nüks oranlarını etkileyen en önemli faktörlerdir.

RETROSPECTIVE ANALYSIS OF RARE BREAST TUMORS

Introduction: Breast cancer can exhibit very different clinical behaviors with different pathological features and biological subgroups. We aimed to present the clinical and demographic characteristics of rare breast tumors operated in a tertiary general surgery clinic. Material and Method: The definitive pathology results of 2427 patients who were operated for breast cancer between January 2010 and January 2021 were retrospectively analyzed. 108 patients with a breast tumor other than invasive lobular carcinoma and invasive ductal carcinoma were included in the study. Surgery types, pathological diagnoses, tumor grade, presence of ulceration on the skin, axilla status, neoadjuvant and adjuvant treatment, recurrence and metastasis status, and survival times of the patients were examined.Results:The age of the patients included in the study was between 30-87 (years) and the median age was 54 years. Of the tumors, 41 (38.0%) papillary carcinoma, 20 (18.5%) metaplastic carcinoma, 15 (13.9%) mucinous carcinoma, 9 (8.3%) apocrine carcinoma, 8 7 (7.4%) medullary carcinoma, 7 (6.5%) malignant phyllodes tumor, 3 (2.8%) acinic cell carcinoma, 2 (1.9%) granular cell carcinoma, 1 (0.9%) was diagnosed as angiosarcoma, 1 (0.9%) as breast metastasis of ovarian carcinoma, and 1 (0.9%) as schwannoma. Breast conserving operation was performed in 60 (55.6%) patients and mastectomy operation was performed in 34 (31.5%) patients. Breast ulceration was observed in 7 of the patients, 5 of them were metaplastic carcinoma, one was medullary carcinoma and the other was angiosarcoma. In total, 16 (14.8%) of 108 patients had more than one tumor. Eleven (68.5%) of 16 patients were found to have papillary carcinoma. The postoperative follow-up period of the patients is between 2-248 months, and the median postoperative follow-up period is 64 months. The number of patients with exitus was 25 (23.1%). Conclusion: Behavioral characteristics of rare tumors in the breast may differ from the more common tumor types. These behavioral differences are the most important factors affecting the expected survival rate and recurrence rates in patients.

PDF

___

1. Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2018; 25(1): 11-20.
2. Blinder V, Eberle C, Patil S, Gany FM, Bradley CJ. Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. Health Aff (Millwood) 2017; 36(2): 274-81.
3. Tagliavini E, Rossi G, Valli R, Zanelli M, Cadioli A, Mengoli M et al. Lymphomatoid granulomatosis:a practical review for pathologists dealing with this rare pulmonary lymphoproliferative process. Pathologica 2013; 105: 111-6.
4. Albagoush SA, Limaiem F. HER2. 2020 Nov 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.
5. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77(2): 181-5.
6. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. Oncologist 2014; 19(8): 805-13.
7. Gudaviciene D, Steponaviciene L, Meskauskas R, Smailyte G, Aleknavicius E. Rare types of breast carcinoma. Open Med (Wars) 2014; 10(1): 92-6.
8. Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019; 11: 151-64.
9. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res 2017; 50(1): 1-23.
10. Sun YS, Zhao Z, Yang, ZN, Xu F, Lu HJ, Zhu ZY et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017; 13(11): 1387-97.
11. Acevedo C, Amaya C, Lopez-Guerra JL. Rare breast tumors: Review of the literature. Rep Pract Oncol Radiother 2013; 19(4): 267-74.
12. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR., Park BH et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat 2019; 173(1): 37-48.
13. Ramezani M, Amirian F, Badfar K, Mohammadi K, Kavousi F, Sadeghi M. Microinvasive Papillary carcinoma of the breast with mucinous differentiation and high grade ductal carcinoma in situ: A case report study. Basic & Clinical Cancer Research 2017; 9(3); 46-9.
14. De Sousa X, Ferreira PS, Martins IL, Rigueira MV. An Unusual case of invasive encapsulated papillary carcinoma of the breast: A case report. Acta Med Port 2020; 33(12): 838-42 (in Portuguese).
15. Piscuoglio S, Ng CK, Geyer FC, Burke KA, Cowell CF, Martelotto LG et al. Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast. NPJ Breast Cancer 2017: 3(1): 1-11.
16. Krings G, Chen YY. Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Mod Pathol 2018; 31(11): 1661-74.
17. Moreno AC, Lin YH, Bedrosian I, Shen Y, Babiera GV, Shaitelman SF. Outcomes after treatment of metaplastic versus other breast cancer subtypes. Journal of Cancer 2020; 11(6): 1341-50.
18. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13(7): 1128–35.
19. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat2008; 111(3): 541–7.
20. Dumitru A, Procop A, Iliesiu A, Tampa M, Mitrache L, Costache M et al. Mucinous breast cancer: a review study of 5 year experience from a hospital-based series of cases. Maedica 2015; 10(1): 14-8.
21. Park S, Koo J, Kim JH, Yang WI, Park BW, Lee KS. Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified. J Korean Med Sci 2010; 25(3): 361–8.
22. Marinova L, Vicheva S, Malinova D. Apocrine Breast Carcinoma-Pathohistological And Immunohistochemical Analysis, Prognosis and Complex Treatment. Med Clin Res 2021; 6(2): 391-4.
23. Maksimiuk M, Budzik MP, Sobiborowicz A, Badowska-Kozakiewicz AM. Apocrine breast carcinoma as an extremely rare breast cancer subtype–histopathological characteristics. Nowotwory. Canc Therapy & Oncol Int J2019; 69(3-4): 83-5.
24. Dai D, Shi R, Wang Z, Zhong Y, Shin VY, Jin H et al. Competing risk analyses of medullary carcinoma of breast in comparison to infiltrating ductal carcinoma. Sci Rep 2020; 10(1): 1-11.
25. Aksoy A, Odabas H, Kaya S, Bozkurt O, Degirmenci M, Topcu TO et al. Hormone receptor status and survival of medullary breast cancer patients: A Turkish cohort. Saudi Med J 2017; 38(2): 156-62.
26. Limaiem F, Mlika M. Medullary Breast Carcinoma. 2021 Jun 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.
27. Chen S, Liu Y, Yang J, Liu Q, You H, Dong Y et al. Comparison of survival outcomes in medullary carcinoma and invasive ductal carcinoma of the breast. Future Oncology 2019; 15(27): 3111-23.
28. Dalcı K, Gul MO, Sarıtaş AG., Gümüş S, Sakman G, Ergin M. Memenin filloides tümörlerinin klinik özellikleri ve süreci. Cukurova Medical Journal 2020; 45(3): 1217-24.
29. Geyer FC, Berman SH, Marchiò C, Burke KA, Guerini-Rocco E, Piscuoglio S et al. Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Mod Pathol 2017; 30(1): 69-84.
30. Adeniran A, AlAhmadie H, Mahoney MC, RobinsonSmith TM. Granular cell tumor of the breast: a series of 17 cases and review of the literature. Breast J 2004; 10(6): 528-31.
31. Corso G, Di Nubila B, Ciccia A, De Camilli E, Vicini E, Trentin C et al. Granular cell tumor of the breast: molecular pathology and clinical management. Breast J 2018; 24(5): 778-82.
32. Kalaycı MU. Primary angiosarcoma of breast. Selcuk Med J 1999; 15(4): 223-5.
33. Alhan D, Güzey S, Aykan A, Şahin İ, Işık S, Yıldız R. Meme koruyucu cerrahi sonrası radyoterapi zemininde gelişen anjiosarkom: Olgu sunumu. Gülhane Tıp Derg 2015; 57(4): 419-22.
34. Ravelomihary TD, Razafimanjato NNM, Nomenjanahary L, Rakototiana AF, Rakotovao HJL, Rakoto-Ratsimba HN. Schwannoma of the breast: a report of rare location and a brief literature review. Ann Breast Surg 2019; 3: 1-5.
35. Stauber J, Chevli N, Haque W, Messer JA, Farach AM, Schwartz MR et al. Prognostic impact of radiation therapy in tubular carcinoma of the breast. Radiother Oncol 2021; 159: 202-8.